Regorafenib (Stivarga) has been approved in Germany since August 2013 for adults with metastatic colorectal cancer in whom previous treatments are no longer effective or for whom these alternatives are not an option. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German IQWiG examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the G-BA. According to the findings, there is a hint of a minor added benefit of regorafenib. Patients have a survival advantage, but certain severe side effects occur more frequently.

For more details, go to: https://www.iqwig.de/en/press/press_releases/press_releases/regorafenib_hint_of_minor_added_benefit.5367.html